Partial vs Full ß-Receptor Agonism: A Clinical Study of Inhaled Albuterol and Fenoterol

Chest

Volumn 109, Issue 4, 1996, Pages 957-962

  Bremner, Peter ^a   Siebers, Robert ^a   Crane, Julian ^a   Beasley, Richard ^a   Burgess, Carl ^a,b  

^a Wellington Asthma Research Group   (United Kingdom)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cardiovascular effects; Intrinsic activity; agonist

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; FENOTEROL; PARTIAL AGONIST; POTASSIUM ION; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; INOTROPISM; MALE; NORMAL HUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; BLOOD PRESSURE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FENOTEROL; HEART; HEART RATE; HUMANS; MALE; MIDDLE AGED; POTASSIUM; RISK FACTORS; SYSTOLE; TIME FACTORS;

EID: 0029924030     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.109.4.957     Document Type: Article

References (41)

1. Ziment I. Beta-adrenergic agonist toxicity: less of a problem, more of a perception. Chest 1993; 103:1591-97
2. Taylor DR, Sears MR. Regular beta-adrenergic agonists: evidence, not reassurance, is what is needed. Chest 1994; 106:552-59
3. Crane J, Flatt A, Jackson R, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case control study. Lancet 1989; 1:917-22
4. Grainger J, Woodman K, Pearce NE, et al. Case control study of prescribed fenoterol and death from asthma in New Zealand, 1981-1987: a further case control study. Thorax 1991; 46:105-11
5. Pearce NE, Grainger J, Atkinson M, et al. Case control study of prescribed fenoterol and death from asthma in New Zealand, 1977-1981. Thorax 1990; 45:170-75
6. Spitzer WO, Suissa S, Ernst P, et al. The use of beta agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501-06
7. Criée C-P, Quast C-H, Lüdtke R, et al. Use of beta agonists and mortality in patients with stable COPD. Eur Respir J 1993; 6(suppl 17):426s
8. Pearce N, Crane J, Burgess C, et al. Beta agonists and asthma mortality: déjà-vu. Clin Exp Allergy 1991; 21:401-10
9. Beasley R, Pearce N, Crane J, et al. Asthma mortality and inhaled beta agonist therapy. Aust NZ J Med 1991; 21:753-63
10. Crane J, Burgess C, Pearce N, et al. The β-agonist controversy: a perspective. Eur Respir Rev 1993; 3:475-82
11. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336:1391-96
12. Stolley PD. Asthma mortality: why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972; 105:883-90
13. Stolley PD, Schinnar R. Association between asthma mortality and isoproterenol aerosols: a review. Prev Med 1978; 7:519-38
14. Brittain RT, Dean CM, Jack D. Sympathomimetic bronchodilating drugs. In: Widdicombe J, ed. Respiratory pharmacology. Oxford, NY: Oxford Pergamon Press, 1991; 613-52
15. O'Donnell SR. An examination of some β-adrenoceptor stimulants for selectivity using the isolated trachea and atria of the guinea-pig. Eur J Pharmacol 1972; 19:371-79
16. Rang HP, Dale MM. Mechanisms of drug action. In: Pharmacology. Edinburgh: Churchill Livingstone, 1987; 33
17. Malta E, Raper C. Non-catechol phenylethanolamines: agonistic actions on β-adrenoceptors in isolated tissues from the guinea-pig. Clin Exp Pharmacol Physiol 1974; 1:259-68
18. Raper C, Malta E. Salbutamol: agonistic and antagonistic activity at β-adrenoceptor sites. J Pharm Pharmacol 1973; 25:661-63
19. Davis C, Conolly ME, Greenacre JK. β-adrenoceptors in human lung, bronchus and lymphocytes. Br J Clin Pharmacol 1980; 10:425-32
20. British Thoracic Society. Guidelines for the management of asthma in adults. BMJ 1990; 301:797-800
21. Lewis RP, Rittgers SE, Forester WF, et al. A critical review of the systolic time intervals. Circulation 1977; 56:146-58
22. Warrington SJ, Weerasuriya K, Burgess CD. Correction of systolic time intervals for heart rate: a comparison of individual with population derived regression equations. Br J Clin Pharmacol 1988; 26:155-65
23. Siebers RWL, Bremner P, Woodman K, et al. Evaluation of the Ionetics electrolyte analyser for plasma potassium measurement in whole blood. NZ J Med Lab Technol 1990; 44:85-6
24. Scheinin M, Koulu M, Laurikainen E, et al. Hypokalaemia and other nonbronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol 1987; 24:645-53
25. Goldie RG, Spina D, Henry PJ, et al. In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, β-adrenoceptor agonists and theophvlline. Br J Clin Pharmacol 1986; 22:669-76
26. O'Donnell SR, Wanstall JC. Evidence that the efficacy (intrinsic activity) of fenoterol is higher than that of salbutamol on β-adrenoceptors in guinea-pig trachea. Eur J Clin Pharmacol 1978; 47:333-40
27. Motomura S, Zerkowski HR, Daul A, et al. On the physiological role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies. Am Heart J 1990; 119:608-19
28. Mugge A, Posselt D, Reimer U, et al. Effects of the beta-2 adrenoceptor agonists fenoterol and salbutamol on force of confraction in isolated human ventricular myocardium. Klin Wochenschr 1985; 63:26-31
29. Brodde OE. The functional importance of beta-1 and beta-2 adrenoceptors in the human heart. Am J Cardiol 1988; 62:24C-9C
30. Strauss MH, Reeves RA, Smith DL, et al. The role of cardiac beta-1 receptors in the haemodynamic response to a beta-2 agonist. Clin Pharmacol Ther 1986; 40:108-15
31. Hazeki O, Ui M. Beta-1 and beta-2 adrenergic receptors responsible for cyclic AMP accumulation in isolated heart and lung cells. Mol Pharmacol 1980; 17:8-13
32. 2 -adrenoceptors in the human heart: properties, function and alternations in chronic heart failure. Pharmacol Rev 1991; 43:204-42
33. Collins JM, McDevitt DG, Shanks RG, et al. The cardiotoxicity of isoprenaline during hypoxia. Br J Pharmacol 1969; 36:35-45
34. McDevitt DG, Shanks RG, Swanton JG. Further observations on the cardiotoxicity of isoprenaline during hypoxia. Br J Pharmacol 1974; 50:335-44
35. Pack RJ, Alley MR, Dallimore JA, et al. The myoardial effects of fenoterol, isoprenaline and salbutamol in normoxic and hypoxic sheep. Int J Exp Pathol 1994; 75:357-62
36. Molfino NA, Nannini LJ, Martelli AN, et al. Respiratory arrest in near-fatal asthma. N Engl J Med 1991; 324:285-88
37. Beasley R, Burgess C, Crane J, et al. Respiratory arrest in fatal asthma. N Engl J Med 1991; 325:205-06
38. Bremner P, Burgess C, Crane J, et al. The cardiovascular effects of fenoterol under conditions of hypoxaemia. Thorax 1992; 47:814-17
39. Heel RC, Brogden TM, Avery GS. Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma. Drugs 1978; 15:3-32
40. Lipworth BJ, Newnham DM, Clark RA, et al. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax 1995; 50:54-61
41. Windom HH, Burgess CD, Crane J, et al. The self-administration of inhaled beta agonist drugs during severe asthma. NZ Med J 1990; 103:205-07